Effect of raloxifene treatment on osteocyte apoptosis in postmenopausal women.
Increased osteocyte apoptosis, as the result of estrogen deficiency, could play a role in the decrease of bone mass and bone strength seen in postmenopausal osteoporosis. We investigated whether treatment with raloxifene of postmenopausal women with osteoporosis affects osteocyte apoptosis. Transiliac bone biopsies were obtained from 26 osteoporotic women at baseline and after 2 years of treatment with placebo or raloxifene. Immunohistochemical detection of cleaved caspase-3 was performed on sections from nondecalcified bone biopsies to visualize apoptosis. In the trabecular bone total osteocytes, positively stained osteocytes and empty lacunae were counted and percent positive cells and percent empty lacunae determined. Statistical evaluation was performed by Wilcoxon's paired t-test and Spearman's rank correlations. There was no significant difference in percentage positive osteocytes between baseline and follow-up biopsies in both the placebo and the raloxifene groups. The percentage empty lacunae increased significantly in the placebo group (11.20 +/- 1.43 vs. 9.00 +/- 2.25, P = 0.014) but not in the raloxifene group. At baseline in both groups combined, there was a negative correlation between indices of bone remodeling and the percentage positive osteocytes (bone formation rate/bone volume r = -0.67, P = 0.001). We found no direct evidence for an effect of raloxifene treatment on osteocyte apoptosis, but small effects of raloxifene treatment cannot be excluded. The percent of apoptotic osteocytes was dependent on the level of bone remodeling in an individual.
Department of Endocrinology, VU University Medical Center, 1007 MB, Amsterdam, The Netherlands. hw.vanessen@vumc.nl
Huib W
HW
van Essen
Paulien J
PJ
Holzmann
Marinus A
MA
Blankenstein
Paul
P
Lips
Nathalie
N
Bravenboer
D017209:Apoptosis / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002452:Cell Count; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D010011:Osteocytes / Q000187:drug effects*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D020849:Raloxifene Hydrochloride